Melanotan II: research overview

L-tyrosine is the direct biochemical substrate of tyrosinase, the rate-limiting copper-dependent enzyme that initiates the Raper-Mason pathway of eumelanin and pheomelanin synthesis. Because melanotan-II is a cyclic analog of alpha-MSH and exerts its pigmentary action through MC1R-mediated upregulation of tyrosinase transcription and activity, tyrosine availability is the downstream substrate that the melanocortin signal acts upon. The pathway is reviewed in Solano 2018. There is no published human trial of L-tyrosine co-administration with melanotan-II specifically; the link is mechanistic, not co-administration data.

Tyrosinase is a type-3 copper metalloenzyme requiring two Cu(II) ions at its active site to catalyze the oxidation of L-tyrosine to dopaquinone. Without adequate copper loading via melanocyte chaperones, the catalytic step downstream of MC1R activation cannot proceed. This is structural enzymology rather than a clinical co-administration study; Solano 2018 reviews the field and notes the copper-zinc distinction across tyrosinase-family enzymes (Trp1 and Trp2 use zinc; tyrosinase itself uses copper). No human trial has examined copper supplementation alongside melanotan-II.

Tyrosinase-related proteins TRP1 and TRP2 (also called DCT) are zinc-dependent metalloenzymes acting downstream of tyrosinase in the eumelanin branch of the Raper-Mason pathway. Borovansky 1994 documents zinc as a feature trace element of pigmented cells and identifies melanosomes as subcellular zinc reservoirs. Adequate zinc supply through ZNT-family transporters is therefore required for the full enzymatic cascade that MC1R activation by melanotan-II upregulates. As with copper, this is mechanistic context rather than peptide-cofactor co-administration data.

In erythropoietic protoporphyria (EPP), the clinical population in which the structurally related melanocortin agonist afamelanotide is the only approved drug, vitamin D deficiency is documented in 46% to 72% of patients due to lifelong sun avoidance. Kluijver and colleagues (2024) showed in a multicentre cohort of 230 EPP patients that afamelanotide treatment alone did not raise serum vitamin D; cholecalciferol supplementation was still required. This is the cleanest published example of an oral co-supplement studied alongside a clinical melanocortin agonist. Relevance to melanotan-II is indirect: shares the same receptor class and the same pigment-population context.